KBC Group’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $209K | Hold |
660
| – | – | ﹤0.01% | 1032 |
|
|
2026
Q1 | $132K | Hold |
660
| – | – | ﹤0.01% | 1152 |
|
|
2025
Q4 | $125K | Hold |
660
| – | – | ﹤0.01% | 1145 |
|
|
2025
Q3 | $117K | Hold |
660
| – | – | ﹤0.01% | 1173 |
|
|
2025
Q2 | $75K | Sell |
660
-244
| -27% | -$26.1K | ﹤0.01% | 1392 |
|
|
2025
Q1 | $95K | Hold |
904
| – | – | ﹤0.01% | 1506 |
|
|
2024
Q4 | $97K | Buy |
904
+300
| +50% | +$33.9K | ﹤0.01% | 1579 |
|
|
2024
Q3 | $60K | Hold |
604
| – | – | ﹤0.01% | 1631 |
|
|
2024
Q2 | $51K | Hold |
604
| – | – | ﹤0.01% | 1598 |
|
|
2024
Q1 | $44K | Hold |
604
| – | – | ﹤0.01% | 1620 |
|
|
2023
Q4 | $43K | Hold |
604
| – | – | ﹤0.01% | 1631 |
|
|
2023
Q3 | $36K | Sell |
604
-625
| -51% | -$41.1K | ﹤0.01% | 1688 |
|
|
2023
Q2 | $89K | Hold |
1,229
| – | – | ﹤0.01% | 1224 |
|
|
2023
Q1 | $90K | Sell |
1,229
-202
| -14% | -$14.4K | ﹤0.01% | 1238 |
|
|
2022
Q4 | $96K | Sell |
1,431
-863
| -38% | -$56.1K | ﹤0.01% | 1217 |
|
|
2022
Q3 | $123K | Hold |
2,294
| – | – | ﹤0.01% | 1107 |
|
|
2022
Q2 | $128K | Buy |
+2,294
| New | +$130K | ﹤0.01% | 1129 |
|
|
2021
Q1 | – | Sell |
-4,639
| Closed | -$288K | – | 1305 |
|
|
2020
Q4 | $288K | Hold |
4,639
| – | – | ﹤0.01% | 967 |
|
|
2020
Q3 | $276K | Buy |
4,639
+2,340
| +102% | +$160K | ﹤0.01% | 917 |
|
|
2020
Q2 | $160K | Sell |
2,299
-32,621
| -93% | -$2.07M | ﹤0.01% | 1107 |
|
|
2020
Q1 | $1.58M | Sell |
34,920
-29,489
| -46% | -$1.67M | 0.01% | 597 |
|
|
2019
Q4 | $4.19M | Buy |
+64,409
| New | +$4.3M | 0.03% | 511 |
|
|
2016
Q1 | – | Sell |
-33,583
| Closed | -$2.27M | – | 1277 |
|
|
2015
Q4 | $2.27M | Sell |
33,583
-3,797
| -10% | -$234K | 0.04% | 445 |
|
|
2015
Q3 | $2M | Buy |
37,380
+35,089
| +1,532% | +$2.13M | 0.04% | 435 |
|
|
2015
Q2 | $144K | Buy |
+2,291
| New | +$125K | ﹤0.01% | 1183 |
|
|
2014
Q4 | – | Sell |
-8,204
| Closed | -$240K | – | 1456 |
|
|
2014
Q3 | $240K | Hold |
8,204
| – | – | 0.01% | 938 |
|
|
2014
Q2 | $319K | Buy |
8,204
+6,853
| +507% | +$278K | ﹤0.01% | 1004 |
|
|
2014
Q1 | $57K | Hold |
1,351
| – | – | ﹤0.01% | 1197 |
|
|
2013
Q4 | $44K | Buy |
+1,351
| New | +$44K | ﹤0.01% | 1236 |
|
Other funds holding LGND
JT
CAM
KBC Group's LGND Position: Q2 2026 in Review
KBC Group held its Ligand Pharmaceuticals (LGND) position steady in Q2 2026 at 660 shares worth $209K. The position accounts for ﹤0.01% of the portfolio, ranked #1032.
KBC Group first reported a position in LGND in Q4 2013 and has held it in 29 quarters since. The position peaked at $4.19M in Q4 2019. 416 funds tracked by Wall St. Rank hold LGND as of Q2 2026.
- KBC Group held 660 shares of Ligand Pharmaceuticals worth $209K as of Q2 2026.
- KBC Group left its Ligand Pharmaceuticals share count unchanged in Q2 2026.
- Ligand Pharmaceuticals made up ﹤0.01% of KBC Group's portfolio in Q2 2026, its #1032 holding.
- KBC Group first reported a position in Ligand Pharmaceuticals in Q4 2013 and has held it in 29 quarters since.
- KBC Group's Ligand Pharmaceuticals position peaked at $4.19M in Q4 2019.
- 416 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.
Based on KBC Group's 13F filing for Q2 2026, filed 5 Aug 2026.